Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 12:10:782.
doi: 10.3389/fonc.2020.00782. eCollection 2020.

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?

Elisena Franzese  1 , Anna Diana  1 , Sara Centonze  1 , Sandro Pignata  2 , Ferdinando De Vita  1 , Fortunato Ciardiello  1 , Michele Orditura  1
Affiliations
Review

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?

Elisena Franzese et al. Front Oncol. .

Abstract

The standard of care for newly diagnosed advanced ovarian cancer (NADOC) is represented by surgical debulking followed by systemic platinum-taxanes combination chemotherapy. At the last European Society for Medical Oncology (ESMO) Congress, results from three trials testing three different poly-adenosine-diphosphate-ribose-polymerase (PARP) inhibitors (olaparib, niraparib, veliparib) in first-line therapy of OC have been presented. For the first time, these studies evaluated the efficacy of PARP inhibitors in this setting and the relative predictive biomarkers for patients' selection. The use of a PARP inhibitor is related with prolonged progression free survival (PFS) in the whole population of NADOC, although the magnitude of benefit varies widely among subgroups, highlighting the need to identify specific biological subtypes into clinical practice. In this minireview, we discuss the updated data available from clinical studies in this scenario.

Keywords: BRCA 1/2 mutation carriers; PARP inhibitor (PARPi); first line; homologous recombination; ovarian cancer.

PubMed Disclaimer

References

    1. Moore K, Colombo N, Scambia G, Kim B, Oaknin A, Friedlander M, et al. . Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. (2018) 379:2495–505. 10.1056/NEJMoa1810858 - DOI - PubMed
    1. Ray-Coquard I, Pautier P, Pignata S, Péro D, González-Martín A, Bergeret R, et al. . Olaparib plusbevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. (2019) 381:2416–28. 10.1056/NEJMoa1911361 - DOI - PubMed
    1. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza M, et al. Niraparib inpatients with newly diagnosed advanced ovarian cancer. N Engl J Med. (2019) 381:2391–402. 10.1056/NEJMoa1910962 - DOI - PubMed
    1. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. . Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. (2019) 381:2403–15. 10.1056/NEJMoa1909707 - DOI - PMC - PubMed
    1. Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, et al. . Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. (2018) 148:507–14. 10.1016/j.ygyno.2017.12.029 - DOI - PubMed

LinkOut - more resources